Identifiable vaginal estradiol acquisition and patient spending among US women aged 55 years and older, 2017–2023

Background We examined identifiable vaginal estradiol acquisition, patient payments, and sociodemographic differences among US women aged 55 years and older. Methods We analyzed repeated cross-sectional MEPS data for 2017–2023. Identifiable vaginal estradiol was designated as the principal cross-year outcome during revision because conjugated estrogen cream was not specifically identifiable after 2020. The study was not preregistered. Survey-weighted estimates and identically specified spending models were reported for 2017–2023 and 2020–2023. Payments were expressed in 2023 US dollars. Results The sample comprised 34,086 person-years from 17,757 women, including 483 estradiol user-years. Acquisition was 1.35% in 2017 and 2.33% in 2023 (adjusted OR per year, 1.15; 95% CI, 1.08–1.22). Mean annual patient payments among estradiol users were $217 in 2017 and $106 in 2023. For 2017–2023, unadjusted and adjusted slopes were −19.53 (95% CI, −34.69 to −4.37) and −18.97 (−33.33 to −4.60) USD per year; corresponding 2020–2023 slopes were −3.73 (−27.61 to 20.14) and −4.66 (−29.22 to 19.90). Pooled acquisition was 0.79% below 200% FPL and 2.54% at or above 400% FPL. Conclusions Recorded vaginal estradiol acquisition was higher in 2022–2023 than in earlier years and differed by income. Mean annual patient payments among women with recorded acquisitions declined over 2017–2023, although the post-2020 OOP trend was uncertain. Public-file identification limits inference about total vaginal estrogen acquisition, GSM treatment coverage, and affordability.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.2008109
Primary Topic
Menopause: Health Impacts and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identifiable vaginal estradiol acquisition and patient spending among US women aged 55 years and older, 2017–2023

Yu-Jun Xiong, Zhen-Jiao Huang, Yao Chen
2 links
Frontiers in Medicine
Menopause: Health Impacts and Treatments
article

Identifiable vaginal estradiol acquisition and patient spending among US women aged 55 years and older, 2017–2023

Yu-Jun Xiong, Zhen-Jiao Huang, Yao Chen
article en

Abstract

Background We examined identifiable vaginal estradiol acquisition, patient payments, and sociodemographic differences among US women aged 55 years and older. Methods We analyzed repeated cross-sectional MEPS data for 2017–2023. Identifiable vaginal estradiol was designated as the principal cross-year outcome during revision because conjugated estrogen cream was not specifically identifiable after 2020. The study was not preregistered. Survey-weighted estimates and identically specified spending models were reported for 2017–2023 and 2020–2023. Payments were expressed in 2023 US dollars. Results The sample comprised 34,086 person-years from 17,757 women, including 483 estradiol user-years. Acquisition was 1.35% in 2017 and 2.33% in 2023 (adjusted OR per year, 1.15; 95% CI, 1.08–1.22). Mean annual patient payments among estradiol users were $217 in 2017 and $106 in 2023. For 2017–2023, unadjusted and adjusted slopes were −19.53 (95% CI, −34.69 to −4.37) and −18.97 (−33.33 to −4.60) USD per year; corresponding 2020–2023 slopes were −3.73 (−27.61 to 20.14) and −4.66 (−29.22 to 19.90). Pooled acquisition was 0.79% below 200% FPL and 2.54% at or above 400% FPL. Conclusions Recorded vaginal estradiol acquisition was higher in 2022–2023 than in earlier years and differed by income. Mean annual patient payments among women with recorded acquisitions declined over 2017–2023, although the post-2020 OOP trend was uncertain. Public-file identification limits inference about total vaginal estrogen acquisition, GSM treatment coverage, and affordability.

Frontiers in MedicineVol. 13
Xiamen University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Beijing Hospital (CN), Zhongshan Hospital of Xiamen University (CN), National Center for Clinical Laboratories (CN)
Good health and well-being, Reduced inequalities
Menopause: Health Impacts and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon